SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after its Q4 earnings report, which, despite solid subscriber growth and ad revenue, prompted a significant stock decline due to conservative Q1 guidance and investor concerns over the proposed Warner Bros. Discovery acquisition. The community is sharply divided; bulls view the deep pullback as an oversold opportunity given strong long-term fundamentals and content potential, while bears focus on the acquisition's cost, debt implications, and paused share buybacks as potential headwinds for future profitability.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is currently trending following a significant 10-year data center lease agreement with Riot Platforms, providing 25 megawatts of capacity with options for substantial expansion, signaling AMD's growing role in AI infrastructure. The community is highly optimistic, noting AMD's consistent strength even on broader market downturns and anticipating continued market share gains amidst surging demand for AI compute.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed Inc. is surging due to its subsidiary, Lucid Diagnostics, securing a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard esophageal DNA test. This news has ignited intense discussion among traders, who are actively debating the potential for continued upside driven by its low float and the strategic importance of expanding esophageal cancer screening across the VA healthcare system, though some express skepticism given the company's past volatility.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is a major discussion point after announcing it met revised 2025 production targets and increased vehicle deliveries, boosted by the Gravity SUV, alongside news of a robotaxi alliance with Uber and Nuro. While some investors see this as a sign of operational progress, community sentiment remains divided, with concerns over long-term profitability, cash burn, and leadership driving ongoing, intense debate within the challenging EV market.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amidst a recent bondholder lawsuit claiming losses due to undisclosed debt related to its AI infrastructure investments, sparking intense community debate about its financial health and market volatility. While many express concern over the substantial debt and recent price declines, others remain optimistic, highlighting an impending TikTok deal and a significant backlog of cloud and AI contracts as key drivers for long-term growth in the evolving tech landscape.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending prominently amidst a flurry of community discussion ignited by its namesake's recent public statements, impacting market sentiment and international relations. A significant short interest is fueling debate among investors, with many anticipating a potential squeeze, while others raise concerns about the company's fundamentals and the ongoing political discourse.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by widespread anticipation surrounding its impending earnings report and recent analyst upgrades. The community is actively discussing the potential for a substantial short squeeze and a sustained upward trajectory, fueled by confidence in its manufacturing advancements and increasing AI server demand. While many foresee a strong breakout, others remain watchful for a 'sell the news' reaction after its impressive run.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a top trending stock after securing a $2.05 million AI licensing partnership in Africa, which includes a pilot program with Nelson Mandela University. The community is intensely focused on the stock's notably low float and high short interest, driving widespread discussion about a potential squeeze. While many anticipate further upside, others express caution, debating the valuation in light of the deal size and raising concerns about potential volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining (HYMC) is trending due to recent high-grade silver drill results and a surge in precious metals prices, fueling speculation about its vast undeveloped resources. The community is sharply divided between those citing billionaire investor Eric Sprott's continued accumulation and short squeeze potential, and others warning about the company's current lack of production and revenue. This dynamic creates a highly contentious and volatile discussion as investors weigh speculative upside against fundamental concerns.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal many view as significant validation for its platform technology. This partnership, involving an upfront payment and potential milestones, is driving discussions about future collaborations and the possibility of a short squeeze due to high short interest. However, some community members are questioning the upfront value and management's approach to capital allocation amidst ongoing calls for stronger shareholder-focused actions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Daily Wegovy pill brings GLP-1 weight loss treatment to U.S. adults

When I first started following news about GLP 1 drugs, everything revolved around injections that patients had to store, handle, and learn to use correctly. Now the arrival of a Wegovy pill in U.S...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Equity

LifeMD Adds Novo Nordisk's Weight-loss Pill Wegovy To Telehealth Platform

(RTTNews) - LifeMD, Inc. (LFMD), a provider of virtual primary care and pharmacy services, on Monday said it is now offering Novo Nordisk's Wegovy pill for chronic weight management and...

LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One...

HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand

Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.

Insider Selling: LifeMD (NASDAQ:LFMD) CMO Sells 15,000 Shares of Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of...

Jessica Friedeman Sells 15,000 Shares of LifeMD (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of...

LifeMD, Inc. (NASDAQ:LFMD) Receives Average Recommendation of "Hold" from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have been given a consensus rating of "Hold" by the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Two...

Hims & Hers Expands Care Scope as Prescription Platforms Evolve

HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.

FY2025 Earnings Estimate for LifeMD Issued By HC Wainwright

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for LifeMD in a research note issued to investors on...

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

LFMD
LifeMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LFMD News

LFMDLifeMD Inc